Paroksismal Noktürnal Hemoglobinüride Uzun Dönem Eculizumab Tedavisi ve Gebelik: Klinik Bir Olgu ve Yönetim Yaklaşımı

Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811. doi:10.1182/blood-2014-02-522128

Parker CJ. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2007;35(4):523–533. doi:10.1016/j.exphem.2007.01.046

Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–1258. doi:10.1056/NEJM199511093331904

Brando B, Gatti A, Preijers F. Flow cytometric diagnosis of paroxysmal nocturnal hemoglobinuria: pearls and pitfalls—a critical review. EJIFCC. 2019;30(4):355–370.

Mastellos DC, Ricklin D, Yancopoulou D, Risitano AM, Lambris JD. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol. 2014;7(5):583–598. doi:10.1586/17474086.2014.953926

Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243. doi:10.1056/NEJMoa061648

Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786–6792. doi:10.1182/blood-2011-02-333997

Manning JE, Ciantar E, Griffin M, Kelly RJ. Paroxysmal nocturnal haemoglobinuria in pregnancy: a systematic review with meta-analysis. Ann Hematol. 2025;104(4):2517–2525. doi:10.1007/s00277-025-06353-7

Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol. 2015;67(1):56–70. doi:10.1016/j.molimm.2015.02.030

Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–1039. doi:10.1056/NEJMoa1502950

Alashkar F, Szer J, Kelly RJ, Patriquin CJ, Höchsmann B, Kulasekararaj A, et al. Eculizumab treatment in paroxysmal nocturnal hemoglobinuria during pregnancy: safety and outcomes. Front Med (Lausanne). 2020;7:543372. doi:10.3389/fmed.2020.543372

Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653–1662. doi:10.1001/jama.293.13.1653

Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–4996. doi:10.1182/blood-2012-09-311381

Peacock-Young B, Macrae FL, Newton DJ, Hill A, Ariëns RAS. The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. Haematologica. 2018;103(1):9–17. doi:10.3324/haematol.2017.177618

Szer J. Extravascular hemolysis in PNH. Blood Adv. 2025;9(19):4977–4978. doi:10.1182/bloodadvances.2025016873

Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(1):230–237. doi:10.3324/haematol.2019.236877

James AH. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Educ Program. 2009;2009(1):277–285. doi:10.1182/asheducation-2009.1.277

Versmold K, Alashkar F, Raiser C, Ofori-Asenso R, Xu T, Liu Y, et al. Long-term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real-world setting. Eur J Haematol. doi:10.1111/ejh.13970